Ejung Moon is a Group Leader in Radiation Biology and the Tumour Microenvironment at the Department of Oncology, University of Oxford's Medical Sciences Division. Her research focuses on hypoxia-driven tumor progression and radiation response mechanisms. Education: PhD in Pharmacology and Cancer Biology from Duke University Training: Postdoctoral work with Amato Giaccia at Stanford University Research Interests: Elucidating how hypoxia-induced MAFF protein regulates tumor cell invasion, metastasis, and radiation resistance through antioxidant response pathways. Current work explores MAFF dimerization dynamics and metabolic reprogramming in hypoxic tumors. Scientific Contributions: Identified MAFF's role in radiation-induced antioxidant gene regulation (2021, Nature Communications ). Recent studies investigate iron metabolism's impact on FLASH radiotherapy effects. Scientific Awards: Breast Cancer Research Program (BCRP) predoctoral fellowship Laboratory & Collaborations: Moon Lab collaborates with Oxford Cancer and NHS Cancer and Haematology Centre. Key partnerships include Stanford University's radiobiology research groups.
Pascal Frossard is a Full Professor at the Department of Electrical Engineering in the School of Engineering (STI) at EPFL, with a courtesy appointment in the School of Computer and Communication Sciences. He founded and directs the LTS4 laboratory since 2003, co-leads the EPFL AI Center and Swiss Data Science Center, and serves as Associate Dean for Research at STI. Research Focus: Machine Learning, Graph Signal Processing, AI Applications in Healthcare, Computer Vision Academic Leadership: IEEE Fellow, ELLIS Fellow, Conference Chair roles Key Projects: Digital Pathology for Oncology, Cardiac Digital Twins, Robust Machine Learning Research Interests: His work bridges signal processing, machine learning, and applied mathematics, emphasizing biomedical applications. Recent research includes adversarial robustness in classifiers, network representation learning, and 360-degree video analysis. Scientific Awards: IEEE Fellow ELLIS Fellow Leadership in IEEE technical committees Advising & Grants: Supervised 20+ PhD students and postdocs. Secured major grants from PHRT, Hasler Foundation, FNS-Sinergia, Armasuisse, Google, and Cisco.
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
Sriram Subramaniam is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia (UBC) and holds the Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design. His research leverages cryo-electron microscopy (cryo-EM) to advance structural biology and drug design, focusing on protein dynamics and therapeutic target identification. Education: PhD in Physical Chemistry (1987) from Stanford University; MSc in Chemistry (1981) from Indian Institute of Technology, Kanpur. Subramaniam's interdisciplinary work combines cryo-EM with computational tools and molecular biology to study protein structures at atomic resolution. His lab has pioneered cryo-EM applications in precision medicine, including mapping small molecule drugs on patient-specific cancer mutants. Recent publications (2024-2022) highlight his contributions to understanding SARS-CoV-2 immune evasion, structural mechanisms of ATPases, and AI integration in structural biology. His research spans viral entry mechanisms, CRISPR systems, and neurodegenerative disease pathways. Scientific Awards: Gobind Khorana Canada Excellence Research Chair NIH Director’s Award for Scientific Excellence Fellow of the Biophysical Society Breakthrough Prize nomination Based at the Djavad Mowafaghian Center for Brain Health, Subramaniam leads the Program in Cryo-EM Guided Drug Design, contributing to over 177 peer-reviewed publications with a career h-index of 58 and citations exceeding 12,340.
Julienne Bower is a Professor at the University of California, Los Angeles (UCLA) with joint appointments in the Department of Psychology and the Department of Psychiatry/Biobehavioral Sciences. She serves as Director of the Mind-Body Research Lab, Associate Director of the Cousins Center for Psychoneuroimmunology, and as a Member of the Jonsson Comprehensive Cancer Center. Her research explores mind-body interactions in individuals facing stressful life events, particularly cancer patients and survivors, focusing on biological pathways linking psychological states to health outcomes and the effects of mind-body interventions. Ph.D. from UCLA Area Chair: Health Psychology Primary Area: Health Psychology Secondary Area: Clinical Psychology Location: 6538 Pritzker Hall, UCLA Dr. Bower's research examines how positive psychological factors (e.g., benefit finding, positive affect) influence physical health through immune and neuroendocrine pathways, while also investigating mind-body interventions like yoga and mindfulness meditation. Her work spans observational, experimental, and intervention studies, emphasizing the immune system as a central mechanism. The Mind-Body Research Lab, under Dr. Bower's leadership, has published extensively on topics including cancer-related fatigue, stress-induced inflammation, and the physiological impacts of psychosocial interventions. Key publications address NF-κB signaling, glucocorticoid resistance, and cortisol dysregulation in cancer survivors. Dr. Bower's lab is actively recruiting graduate students for 2024 through the UCLA Health Psychology Program, offering training in psychoneuroimmunology, cancer prevention, and mind-body research methodologies.
Andrew Holle is an Assistant Professor at the Mechanobiology Institute , National University of Singapore , where he leads the Confinement Mechanobiology Lab within the Department of Biomedical Engineering . His work spans mechanobiology, stem cell differentiation, cancer mechanobiology, and microfluidics, with a focus on understanding how physical confinement influences cellular behavior. Education: B.S.E. in Bioengineering (Minor in Statistics), Arizona State University (2008) Ph.D. in Bioengineering, University of California San Diego (2013) Research in the Confinement Mechanobiology Lab centers on the hypothesis that stem cell differentiation is driven by mechanical cues during migration through confined extracellular matrix (ECM) environments. The lab develops microfluidic systems to mimic ECM confinement and studies its impact on osteogenic differentiation , cancer cell migration , and cellular condensates . Recent publications highlight interdisciplinary approaches combining mechanobiology , nanotechnology , and microfluidics to explore nuclear morphological changes, volume regulation, and ligand signaling in confined cellular environments. Laboratory Members: Privita Edwina (Research Fellow) Vaishnavi Rangaraj (Research Assistant) Sriram Muthukumar (Research Fellow) Chang Ye Ji (PhD Student) Gao Xu (PhD Student) Lim Yuan Bin (PhD Student) Shinny Sunny (PhD Student) Lee Jia Wen Nicole (PhD Student) Li Yixuan (PhD Student)
Roles & Affiliations: Ikhlas Khan serves as Director of the National Center for Natural Products Research (NCNPR), Distinguished Professor, and Research Professor of Pharmacognosy at the University of Mississippi's School of Pharmacy. He also leads the FDA Program and coordinates natural products research across multiple initiatives, including the Sino-US TCM Research Center and the Center for Research of Indian Systems of Medicine (CRISM). Education: B.Sc. Chemistry (1980) - Aligarh Muslim University, India M.Sc. Organic Chemistry (1982) - Aligarh Muslim University, India Ph.D. Pharmacy (1987) - Ludwig-Maximilians-Universität, Munich Postdoctoral Studies - Swiss Federal Institute of Technology (ETH), Zurich Research Focus: Dr. Khan specializes in natural products research with emphasis on: Phytomedicine: Standardization of herbal products via analytical fingerprinting, pesticide/herbicide residue analysis, and bioanalytical quality control. Drug Discovery: Isolation of bioactive natural products, development of analytical methods for phytochemical characterization, and chiral separation techniques. Metabolism Studies: Role of metabolism in drug/natural product activity, particularly in aminoquinoline antimalarials. His work bridges academia, industry, and regulatory bodies, shaping policies for botanical supplements. Key Contributions: Over 850 peer-reviewed publications and leadership in high-impact projects like the FDA Center of Excellence. His lab pioneered methods to combat herbal product adulteration and safety issues. Awards & Recognition: UM Distinguished Professor Award (2018) Wiley Award (AOAC International, 2018) Qihuang International Prize (2017) Honoris Causa Doctorate (University of Hamdard, 2012) Labs & Collaborations: Directs the NCNPR, a global leader in natural products research, and collaborates with institutions worldwide. His team develops technologies for herbal product authentication and drug metabolism studies.
Karen Piper Hanley is Professor of Molecular Medicine and Head of Division in the Division of Diabetes, Endocrinology & Gastroenterology at the University of Manchester. She serves as the fibrosis lead in the Wellcome Trust Centre for Cell-Matrix Research and previously served as Director of Core Research Technologies (2019-2022). She is also an editorial board member for Scientific Reports. Her research focuses on fibrosis (scarring) mechanisms across multiple organs, particularly liver, kidney, and lung fibrosis. Her lab investigates the cellular and molecular basis of fibrotic disease, with emphasis on how pathological scar components are produced and how they signal to surrounding cells. Key areas include the role of SOX9 transcription factor, integrin beta-1 signaling, Group 1 PAKs, and YAP1 in fibrosis progression. Her recent publications reveal trends toward increased clinical translation of fibrosis research, with studies on health inequalities in liver cancer care, post-COVID diabetes incidence, and innovative approaches to liver disease detection. Her work increasingly integrates spatial transcriptomics and advanced omics technologies to understand cellular transitions in liver disease. Career-track postdoctoral fellowship from the University of Southampton (2006) As senior postgraduate tutor, she has mentored numerous PhD students who have presented at key conferences and authored high-quality manuscripts. All her PhD students have submitted and been awarded their degrees within 4 years. She has successfully guided previous Academic Clinical Fellows to win MRC clinical training fellowships. Her teaching extends to undergraduate Personal & Professional Development and supervision of MRes and BSc students, many of whom have achieved first-class degrees and prestigious awards. Her lab maintains active collaborations with Professor Neil Hanley's group on human development, stem cells, and regenerative medicine, bridging developmental biology with fibrosis research to understand why regeneration is impaired in chronic diseases.
Dr. Giulia Biancon is an Assistant Professor Adjunct in the Department of Medical Oncology and Hematology at Yale School of Medicine. She holds a PhD from the University of Milan (2019) and is a member of the Halene Lab, focusing on RNA biology and hematologic malignancies. Her research combines high-throughput methodologies to study RNA mechanisms in diseases like myeloid leukemias and splicing factor mutations. Education: PhD in Molecular Biology from the University of Milan (2019). Research Interests: RNA splicing, stress granules in cancer, epitranscriptomics, clonal hematopoiesis, and the interplay between genetic mutations and cellular pathways in blood cancers. Awards: 2024 Eclipse Award, 2022 ASH Abstract Achievement Award, and 2022 RNA Society Best Poster Award. Her work has been published in journals like Cell Reports , Blood , and Molecular Cell . Labs/Teams: Principal member of the Halene Lab and coordinator at the Yale Center for RNA Science and Medicine. Collaborates with institutions like the SeroNet network for immunology studies.
Dr. Pascal Syren is a **Researcher** and **Resident** at Heidelberg University Hospital (UKHD), affiliated with the **Department of Cardiology, Angiology, and Pulmonology** and the **Heidelberg Center for Cardiac Arrhythmias**. His academic role includes contributing to the **Group of Molecular and Translational Cardiac Electrophysiology**, focusing on epigenetic and molecular mechanisms underlying cardiac arrhythmias and heart failure. He holds a PhD from Heidelberg University (2021) on histone deacetylases' influence in cardiac electrophysiology. **Research Interests**: Cardiac electrophysiology, epigenetic regulation (HDACs), ventricular and atrial arrhythmias, echocardiography, and translational cardiology. His work spans basic science to clinical applications, emphasizing ion channel remodeling and therapeutic targets for heart rhythm disorders. **Awards**: Recipient of the **Ernst & Berta Grimmke Foundation Research Grant (2023–2024)** and **Otto-Hess Scholarship (2017–2018)** from the German Cardiac Society. His research bridges molecular mechanisms with clinical cardiology, with contributions to understanding HDAC2's role in action potential dynamics. **Publications**: Over 8 peer-reviewed articles (2016–2025) in journals like *Basic Research in Cardiology* and *Cells*, focusing on histone deacetylase pathways, atrial fibrillation, and ventricular arrhythmia models. Recent work explores neonatal cardiomyocyte electrophysiology and TREK-1 potassium channels in heart failure. **Affiliations**: Active member of the **German Cardiac Society (DGK)** and **European Society of Cardiology (ESC)**, contributing to interdisciplinary cardiac arrhythmia research at Heidelberg's medical faculty.
Dr. Rebecca Pratt is a tenured Professor in the Department of Foundational Medical Studies at Oakland University William Beaumont School of Medicine (OUWB), where she has been a faculty member since January 2018. She previously held professorial roles at Michigan State University College of Osteopathic Medicine (MSUCOM), where she taught anatomy, embryology, neuroanatomy, physiology, and histology, and served as Associate Professor and Director of Histology at the West Virginia School of Osteopathic Medicine. She also held appointments at Grand Valley State University and completed postdoctoral training at Purdue University. Ph.D., Cell Biology and Oncology, Purdue University B.S., Zoology and Botany/Plant Pathology, Michigan State University Dr. Pratt's research focuses on the fascial system and its role in whole-body health, including fascial continuity, muscle attachment, somatic pain transmission, and biochemical communication. She integrates radiology into anatomy education and advocates for evidence-based medical curricula. Her work bridges clinical anatomy, histology, embryology, and physiology with modern educational practices. Her recent publications reflect a strong emphasis on fascial anatomy, medical education innovation, and the integration of imaging in teaching. Themes include plastination, generational learning trends, and fascia’s role in women's health and athletic performance, published in journals like Clinical Anatomy and Anatomical Sciences Education , as well as in Women and Men’s Health and NIKE magazines. Scientific awards and honors include: Basmajian Award (American Association of Anatomy) Keith and Marion Moore Award (AAA) Five consecutive Golden Apple Teaching Awards at MSUCOM Golden Apple Award at OUWB Dr. Pratt has served in major leadership roles, including President of the International Fascia Research Society, Board Member of the American Association of Anatomy (AAA) and the American Association of Clinical Anatomy (AACA), and Chair of multiple AAA committees. She is a Visiting Anatomy Professor at Weill Cornell and St. George’s University School of Medicine, and faculty advisor for the Docapellas at OUWB. She has been an invited speaker internationally and contributed to high-impact projects like the BodyWorlds Fascial Net Plastination Project. She actively serves on OUWB’s Admissions and Student Promotion and Retention Committees. Dr. Pratt leads and organizes major international initiatives, including the Women's Clinical Health Summit in Rio de Janeiro (2024) and the Fascia Research Congress in New Orleans (2025), fostering global collaboration in fascial science. Her lab and research team focus on fascial anatomy and medical education, working closely with institutions in Italy (University of Padova) and Germany (BodyWorlds project).
Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.
